Strategic partnerships Omeros has recently secured a high-value deal with Novo Nordisk worth up to $2.1B to develop and commercialize zaltenibart, signaling strong collaboration potential with large pharma for rare disease and specialty programs.

Rare disease focus The company targets inflammation, coagulopathies, and CNS disorders with both small molecules and proteins, including hematology/immune-mediated conditions and TA-TMA, indicating multiple orphan and niche indications ripe for co-development, licensing, or milestone-driven partnerships.

Clinical and regulatory momentum Omeros is advancing clinical-stage therapies such as OMS527 for CUD at NIDA’s request and highlighting TA-TMA programs at industry events, suggesting ongoing clinical activity and potential windows for collaboration, advisory roles, or joint development arrangements.

Commercial leadership Recent leadership changes in commercial and medical roles plus a FDA-approved first-in-class treatment (Yartemlea) signal ongoing commercialization builds and opportunities to engage in distribution, market access, or specialty sales partnerships for hematologic conditions and transplant-related indications.

Public momentum Deal recognition and media coverage around the Novo Nordisk collaboration indicate strong market visibility and a favorable narrative for investment and partnering discussions, making it easier to position co-development or licensing pitches to senior decision-makers.